FIA
OCUL icon

FNY Investment Advisers’s Ocular Therapeutix OCUL Stock Holding History

FNY Investment Advisers’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Sell
150
-20
-12% -$181 ﹤0.01% 798
2026
Q1 		$1K Buy
+170
New +$1.62K ﹤0.01% 714

Other funds holding OCUL

EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
RZH
Relyea Zuckerberg Hanson Stamford, Connecticut $1.2B AUM 28.45% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

FNY Investment Advisers's OCUL Position: Q2 2026 in Review

FNY Investment Advisers reduced its Ocular Therapeutix (OCUL) stake by 12% in Q2 2026, selling an estimated $181 and leaving 150 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

FNY Investment Advisers first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • FNY Investment Advisers held 150 shares of Ocular Therapeutix worth $1K as of Q2 2026.
  • FNY Investment Advisers sold 20 Ocular Therapeutix shares in Q2 2026, an estimated $181.
  • Ocular Therapeutix made up ﹤0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #798 holding.
  • FNY Investment Advisers first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.